



ISSN Print: 2664-9926
 ISSN Online: 2664-9934
 NAAS Rating: 4.82
 IJBS 2025; 7(6): 238-245
www.biologyjournal.net
 Received: 03-04-2025
 Accepted: 05-05-2025

Sneha Sheshrao Shrugare
 Biomedical Science, School of
 Allied Health Sciences, Datta
 Meghe Institute of Higher
 Education and Research,
 Wardha, Maharashtra, India

Prashik Dube
 Department of Radiotherapy,
 School of Allied Health
 Sciences, Datta Meghe
 Institute of Higher Education
 and Research, Wardha,
 Maharashtra, India

Dr. Ashwini Aher
 Department of Biomedical
 Sciences, School of Allied
 Health Sciences, Datta Meghe
 Institute of Higher Education
 and Research, Wardha,
 Maharashtra, India

Dr. Sunil Thitame
 School of Allied Health
 Sciences, Datta Meghe
 Institute of Higher Education
 and Research, Wardha,
 Maharashtra, India

Corresponding Author:
Sneha Sheshrao Shrugare
 Biomedical Science, School of
 Allied Health Sciences, Datta
 Meghe Institute of Higher
 Education and Research,
 Wardha, Maharashtra, India

An AI-enabled single-cell approach to analyze the cancer immune microenvironment

Sneha Sheshrao Shrugare, Prashik Dube, Ashwini Aher and Sunil Thitame

DOI: <https://www.doi.org/10.33545/26649926.2025.v7.i6d.383>

Abstract

Recent advances in single cell research enable analysis of specific immune cell populations within the cancer-specific tumor microenvironment (TME). Artificial intelligence (AI) has emerged as a key technology, utilizing machine learning and deep learning methodologies, and is capable to analyze single-cell RNA-Seq and domain level data to provide unprecedented insights into immune responses and tumor-immune interactions. The present work utilizes AI-based methods to explore two paths in cancer immunology through single cell transcriptomics and spatial multi-omics to study tumor evolution, immune escape, and resistance to immune-based therapy. AI methods can classify tumor infiltrating lymphocytes (TILs), establish functional immune cell states and assess patient-specific ICI responses. AI methods are also effective at developing novel immune biomarker discovery and therapeutic predictive response with high-dimension single cell data datasets. We further explore both AI models and single cell analysis integration with scRNA-seq in conjunction with spatial transcriptomics to help assess dynamics of immune and TME interactions and where to focus and evaluate immunotherapy strategies. This paper offers insight as AI leads to a rebirth in cancer immunology through biomarker discovery, patient stratification, and world's precision immunotherapy based on subsets of immune recognition. AI-enabled analysis of single-cell data demonstrates a considerable development toward agnostic personalized cancer therapy and clinical impacts for defined cancer pathways.

Keywords: Cancer immune microenvironment, single-cell analysis, artificial intelligence, tumor immunology, machine learning, bioinformatics.

Introduction

The Tumor Immune Microenvironment (TIME) is important for cancer progression and responses to therapies. It consists of a variety of immune components, stroma, and signalling molecules that are in a state of reciprocal dynamic interaction with tumor cells that influence the disease course. An intact immune microenvironment will lead to tumor destruction, while an immunosuppressive TIME will enhance tumor immune evasion and resistance to therapy, including immunotherapy. Knowledge of the complexities of cellular heterogeneity within TIME is critical for developing novel therapeutic strategies. Single cell analysis has transformed our understandings of cancer biology by allowing detailed resolution of various cell populations within the tumor microenvironment. Single cell technologies, such as single-cell RNA sequencing (scRNA-seq), mass cytometry (CyTOF), and spatial transcriptomics provide information about specific immune subtypes present in the TIME, their functional states, and physical interactions with tumors. Such detailed analyses provide a critical level of understanding of the biological concepts underlying immune evasion, therapy resistance, and tumor progression.

Artificial intelligence (AI) has become a powerful mechanism for analyzing and interpreting the complex and large amounts of data generated by single-cell methodologies. Artificial intelligence methods, including deep learning and machine learning algorithms, enable automated cell-type annotation, clustering, and predictive modelling of immune interactions. These methods allow enhanced capability for analysis of large datasets at single-cell resolution, thus yielding valuable biological and functional data, and notably, enabling identification of potential biomarkers for personalized anticancer treatment.

The review integrates the application of AI-enhanced single-cell strategies in the exploration of the cancer immune microenvironment. It will present a broad overview of important single-cell technologies, the AI approach used to convert data to biological relevance in the arena of immunology, and will describe their application to cancer immunology. Finally, we will present some challenges with AI strategies and examine the potential future developments of AI in single-cell research and its impact on cancer immunotherapy.



Fig 1: AI - Driven Cancer Immunology Insights

Research Methodology

This review utilizes a systematic and literature review to examine AI-enhanced single-cell approaches for analysis of the cancer immune microenvironment. Peer-reviewed journals, clinical trials, and recent advances were retrieved from databases like PubMed, Scopus, and Google Scholar.

Criteria for selection favoured studies published within the past decade that emphasize AI-powered single-cell transcriptomics, imaging technology, and computational tools for immune profiling. Emerging findings were integrated to assess prevailing trends, issues, and promising directions in the union of AI and single-cell analysis in cancer immunology.

The Cancer Immune Microenvironment (TIME)

Tumor immune microenvironment (TIME) is a dynamic and intricate ecosystem, comprising a heterogeneous subset of immune cells, stromal components, signal molecules, and extracellular matrix components, in total controlling the development of tumors and treatment outcomes ^[1]. Immune cells like T cells, B cells, macrophages, dendritic cells, and natural killer (NK) cells play pivotal roles either promoting or suppressing cancer growth ^[2]. Among these, T cells, more precisely cytotoxic CD8 T cells, form a key member in the field of anti-cancer immunity, while regulatory T cells (Tregs) and tumor-associated macrophages (TAMs) form part of creating an immunosuppressive tumor microenvironment ^[3]. B cells can depict both pro- and anti-cancer functions, while dendritic cells are antigen-presenting cells and therefore induce T cell activation. NK cells, as part of innate immunity, have the ability for killing cancer cells without the need for sensitization in advance ^[4]. Moreover, stromal cells, fibroblasts, cytokines, chemokines, and extracellular matrix components, along with immune cells in combination, form a pro-oncogenic tumor microenvironment conducive to the recruitment of immune cells and cancer growth.

Table 1: Key Immune Components in the Tumor Immune Microenvironment (TIME)

Component	Function
Cytotoxic CD8+ T Cells	Kill tumor cells via cytotoxic granules
Regulatory T Cells (Tregs)	Suppress immune responses to maintain self-tolerance
Tumor-Associated Macrophages (TAMs)	Promote tumor progression through immune suppression
Natural Killer (NK) Cells	Kill tumor cells without prior sensitization
Dendritic Cells (DCs)	Present antigens to activate T cells
B Cells	Play both pro- and anti-tumorigenic roles

The interaction of neoplastic cells and immune cells in the tumor microenvironment (TIME) dictates the fate of progression towards immune activation or immune evasion in neoplasms ^[5]. Tumor cells can subvert the host immune system via the upregulation of immune checkpoint molecules (e.g., PD-L1, CTLA-4), which can inhibit T cell activation and confer immune escape properties ^[6]. In addition, tumor cells secrete immune suppressive cytokines (e.g., TGF- β , IL-10) to attract regulatory immune cells while also inhibiting the cytotoxic immune response. These immune-tumor cell interactions help create an immune privileged environment that allows tumor cells to persist and progress. The paradigm of TIME as a key concept in cancer treatment remains constant, especially in immuno-oncology strategies. Immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA-4 monoclonal antibodies, have fundamentally changed the way we treat patients with malignancies, restoring long lasting anti-tumor immunity ^[7]. However, we recognize that the TIME in some patients does not respond to immunotherapy, thus evidence for precision medicine is needed. Analyzing the cellular and molecular components of the TIME may provide insights on potential

mechanisms of resistance and novel drug targets. In particular, as we utilize emerging tools in the field to identify and analyze the TIME (i.e., single-cell, or AI) we not only further our understanding, but also the therapeutic potential of targeting the TIME property in patients with tumors.

Single-cell Technologies for Analyzing TIME

Single-cell RNA sequencing (scRNA-seq) is a significant technique for examining tumor immune microenvironment (TIME) cellular heterogeneity with a higher resolution than bulk RNA-seq, which averages gene expression in a heterogeneous cell population ^[8]. By analyzing gene expression at the single-cell level, scRNA-seq allows for thorough investigations of the various immune cell subsets, their functional states, and their dynamic interactions with tumor cells. The scRNA-seq procedure is defined by several important steps which include single-cell isolation, mRNA capture, reverse transcription, cDNA amplification, library preparation, and next-generation sequencing (NGS) ^[9]. A variety of platforms exist to perform single-cell transcriptomic analysis utilizing either droplet technology

(10x Genomics Chromium) or plate-based methods (Smart-seq2) ^[10]. A bioinformatics analysis pipeline which includes quality control, dimensionality reduction, clustering, and

differential gene expression analysis is subsequently developed for scRNA-seq data analysis and interpretation to handle the large data generated from this technique ^[11].

Table 2: Single-cell Technologies for Analyzing TIME

Technology	Description
scRNA-seq	Analyses gene expression at the single-cell level
Mass Cytometry (CyTOF)	Measures protein expression at a high resolution
Spatial Transcriptomics	Maintains spatial organization of cells while analyzing gene expression
Multiplex Imaging	Uses fluorescent markers to visualize immune cells within the tumor

Single-cell RNA sequencing (scRNA-seq) analysis of the tumor immune microenvironment (TIME) has dramatically augmented our understanding of immune cell states, their plasticity, and their functions within the tumor microenvironment ^[12]. scRNA-seq facilitates the capture of rare populations of immune cells, including exhausted T cells, suppressive T cells, and tumor-associated macrophages, all of which have essential regulatory functions within the context of anti-tumor immunity. scRNA-seq allows the reconstruction of transcriptional landscapes of immune cell fates responding to heterogeneous stimuli, including treatment with immunotherapy or upon the progression of a tumor ^[13]. Reconstruction of immune cell differentiation and lineage tracking using scRNA-seq will be able to reveal critical signalling pathways that lead to activation or suppression of the immune system within TIME. In addition, scRNA-seq can also be used in conjunction with other single-cell-based technologies such as spatial transcriptomics and proteomics to provide deeper insights into the localization of immune cells and their interactions with tumor cells ^[14]. Collectively, these insights are essential for uncovering new immunotherapy targets and developing individualized cancer therapies which exploit the unique immune contexture of each tumor.

Single-cell Proteomics and Mass Cytometry (CyTOF)

Single-cell proteomics enables high-dimensional analysis of

protein expression at single-cell resolution using mass cytometry (CyTOF), which is widely known as a cutting-edge technology ^[15]. Mass cytometry is preferable to other approaches to gene expression, such as scRNA-seq, because CyTOF examines proteins (which are functional molecules driving immune responses) instead of relying on measuring gene expression. CyTOF works similarly to flow cytometry but combines it with mass spectrometry ^[16]. In other words, CyTOF utilizes antibodies with heavy metal labeling to detect protein expression on the single-cell level. While flow cytometry is limited in measuring two to four fluorescent labels (not accounting for reactivity), mass cytometry overcomes this by detecting protein expression using over 50 different immune markers or protein labels, without overlapping signals. With this technology, we can obtain a very detailed picture of immune cell phenotyping and functional states in the tumor immune microenvironment (TIME). In short, CyTOF is a powerful technique that can be used to analyze immune cell populations that engage with the tumor microenvironment, including cytokine production capacity, foreign antigen expression, or signaled miRNA from kinases ^[17]. The workflow of CyTOF involved preparing single-cell suspension, staining using specific metal tagged antibody probes, analyzing on time-of-flight mass cytometer, and then analyzing data using computational clustering methods to explain and organize the identity of various immune cell populations.




Fig 2: CyTOF Workflow in Analyzing Tumor Microenvironment

CyTOF has provided a tremendous opportunity to characterize immune cell subsets in the TIME by enabling multifaceted phenotypic and functional characterization. CyTOF permits the characterization of rare immune cell

subpopulations, including exhausted T cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) that are often implicated in tumor progression and tumor-mediated immune evasion ^[18].

CytoTOF can also interrogate the functional states of immune cells, including measuring secretion of cytokines, expression of activation markers, and assessing downstream intracellular signalling pathways, facilitating our understanding of the immunological responses to therapies, including immune checkpoint inhibitor therapy. The integration of CyTOF with other single-cell approaches (e.g., spatial proteomics and transcriptomics) greatly increases the ability to interrogate immune cell interactions and the spatiotemporal organization of immune cells into the tumor microenvironment [19]. Overall, the diverse functional information that is generated provides a rich proteomic landscape of the TIME that can be used to develop precision immunotherapy approaches tailored to the immune profile of an individual patient.

Spatial Transcriptomics and Multiplex Imaging

Gaining insight into the distribution of immune cells within the tumor-immune microenvironment (TIME) is important for understanding tumor-immune interactions, the response to immunotherapy, and the mechanisms of immune evasion [20]. While single-cell RNA sequencing (scRNA-seq) provides high-dimensional transcriptomic information, it does not provide information about spatial context, so it is often used to assess the distribution of immune cells, among other activities, within the relevant tumor tissue. Spatial transcriptomics and multiplex imaging methods address this limitation by maintaining the spatial organization of the cells while quickly acquiring their molecular profile. Thus, researchers can assess the localization of immune cells, cell-to-cell interactions, and organization relative to TIME, and help us understand tumor-immune interactions.

Complex spatially resolved single-cell technologies have emerged to facilitate single-cell analysis. An example is CODEX (CO-Detection by Indexing), a multiplexed imaging platform which utilizes antibody-based fluorescent barcoding designed to visualize multiple protein markers within intact tissue sections as an avenue for high-dimensional immune cell phenotyping [21]. An additional emerging technology in spatial transcriptomics, known as (MERFISH), multiphase error-responsive fluorescence in situ hybridization enables single molecule RNA detection while preserving tissue architecture to generate spatial maps

of TIME gene expression. Spatial transcriptomics methods, including 10x Genomics Visium and NanoString, adapt the barcoded mRNA capture grid to overlay transcriptomic data with histological images, allowing preservation of spatial information [22]. Regardless of the specific methodology, this technology provides the opportunity to elucidate in addition, the incorporation of spatial transcriptomics with artificial intelligence (AI) based image analysis enhances the overall interpretation of the spatial immune landscape, and in the lead up to developing more precise and efficacious cancer immunotherapies. Immune cell niches, tumor-immune borders, and spatially regulated immune responses that are pertinent to understanding immunotherapy resistance, and ultimately implementing interventions based on spatial information to enhance therapeutic response.

AI and Machine Learning in Single-cell Analysis of TIME

The field of artificial intelligence (AI) and machine learning (ML) has transformed the analysis of single cell data because it allows for the rapid, efficient processing, clustering, and interpretation of the enormous and complex datasets generated by single-cell RNA sequencing (scRNA-seq), proteomics, and spatial transcriptomics in the context of high-throughput omics methods [23]. A primary challenge associated with single-cell data is high Both t-SNE and UMAP allow the projection of high-dimensional data into lower-dimensional space in such a way that local structure reflective of cellular relationships is maintained, while facilitating visualization of tumor immune microenvironments (TIME) cell populations. Dimensionality, where thousands of genes or proteins are measured in thousands to millions of individual cells. AI-powered pre-processing functions and dimensionality reduction tools such as principal component analysis (PCA), t-distributed stochastic neighbouring embedding (t-SNE), and uniform manifold approximation and projection (UMAP), simplify high dimensionality data while preserving essential biological information [24]. PCA facilitates high dimensionality reduction by identifying the principal components with the greatest amount of variance in the dataset.

Table 3: AI Methods in Single-cell Analysis

AI Method	Application in TIME Analysis
Machine Learning	Clustering, feature selection, and predictive modelling
Deep Learning	Automated classification of immune and tumor cell types
Transfer Learning	Adapts models across different datasets
Graph Neural Networks	Models immune-tumor cell interactions
Explainable AI	Enhances interpretability of AI-based predictions

Following dimensionality reduction, clustering algorithms are essential in identifying unique populations of immune cells with distinct functional states. There are traditional approaches utilizing methodologies such as k-means clustering where cells are assigned to previous arrangements based on a similarity of gene expression; and more sophisticated approaches employing graph-based clustering methodologies like Louvain and Leiden algorithms where models create networks of cells to identify communities of similar cells [25]. Clustering can reveal overall diversity in a sample, identify rare subtypes of immune cells, aid in understanding immune activation states, and expose the

relationship between the tumor and immune cells in the tumor-immune microenvironment (TIME) that may be immunologically relevant. Machine learning-based clustering can better identify these relevant immune signatures for cancer progression, response to immunotherapies, or resistance mechanisms. With continuing adaptations of AI-based models, along with advances in single-cell technologies, AI implementation in single-cell approaches will furthermore deepen our knowledge of TIME leading to precision in cancer immunotherapy design and personalization [26].

Deep Learning for Single-cell Classification

Deep learning techniques have played a notable role in advancing single-cell analysis through automated and accurate classification of immune and tumor cell types within the tumor immune microenvironment (TIME) [27]. Traditionally, most types of single cell classification utilize marker genes for manual annotation, which can be tedious and potentially biased. Deployment of deep learning-based approaches or artificial neural networks (ANN) and convolutional neural networks (CNN), have become a tool for cell type annotation by learning complex patterns from high-dimensionality single-cell expression data. Deep learning models can classify immune cells subtypes such as CD8+ cytotoxic T cells, CD4+ regulatory T cells, tumor associated macrophages (TAM), and natural killer (NK) cells, based on their gene expression (mRNA) or protein profiles [28]. When trained on a very large number of single-cell RNA sequencing (scRNA-seq) or proteomics datasets, deep learning models increase the efficiency and accuracy of cell classification and identification of novel cell states and functional phenotypes in TIME.

One of the biggest challenges in single-cell research is heterogeneity in data across platforms, experimental conditions, and cancer types. Transfer learning tackles this challenge by enabling deep learning models to be trained on one dataset and easily applied to new datasets with minimal extra training. This makes large annotated datasets less necessary and enhances model generalizability across cancer types. Self-supervised learning techniques also enable deep learning models to acquire useful representations of single-cell data without heavy manual annotation [29]. With the help of contrastive learning or autoencoders, the models can acquire the underlying biological patterns and identify rare immune cell populations in TIME. The integration of deep learning with single-cell analysis is transforming cancer immunology by making more accurate and scalable cell classification techniques, which ultimately give rise to new immunotherapy targets and personalized therapies [30].

Predictive Modelling of Immune Interactions

Artificial intelligence (AI) is increasingly used to predict interactions between immune cells and tumors in the tumor immune microenvironment (TIME), thus offering vital information on cancer initiation and treatment response [31]. The complex dynamics of cellular signalling, cytokine communication, and immune checkpoint interactions enable the complex interactions between immune cells and tumor cells. AI-based models utilize high-dimensional single-cell data to model the interactions, which reveal key molecular factors that determine whether immune cells elicit an effective anti-tumor response or enable immune evasion. Graph neural networks (GNNs), network-based modelling, and agent-based simulations are used to reconstruct immune-tumor interaction networks, predicting the responses of different immune cell populations, including cytotoxic T cells and tumor-associated macrophages, to different tumor phenotypes [32]. These AI-based predictions enable the identification of potential immune vulnerabilities in tumors, thus informing the design of new therapeutic approaches.

AI is also transforming response prediction to immunotherapy, solving the issue of heterogeneity of patient response to ICIs and other immunotherapies [33]. Machine learning algorithms trained from single-cell transcriptomics,

proteomics, and spatial omics can predict biomarkers for response or resistance to treatment. Deep learning models integrate features such as T cell exhaustion biomarkers, tumor mutational burden, and immune infiltration patterns to classify patients as responders and non-responders [34]. AI-based predictive models also aid in predicting the effect of different immunotherapies on TIME, enabling personalized treatment suggestion. Through AI-aided immune interaction modelling and prediction of response to therapy, researchers are enabled to accelerate discovery of precision immuno-oncology approaches, ultimately contributing to improved patient outcomes in cancer treatment.

AI-powered Spatial Transcriptomics Analysis

Artificial intelligence (AI) is revolutionizing the area of spatial transcriptomics by enabling the integration of spatial and single-cell transcriptomic data to improve understanding of the tumor immune microenvironment (TIME). Traditional spatial transcriptomics methods provide high-resolution maps of gene expression with tissue structure preservation; however, analysis of these complex datasets requires advanced computational methods [35]. AI-powered frameworks, including deep learning and probabilistic graphical models, enable smooth integration of spatial and single-cell data to allow researchers to identify spatially heterogeneous niches of immune cells and identify regulatory interactions between immune and tumor cells. Employing AI-driven clustering and dimensionality reduction algorithms, researchers can map functional immune states in TIME and thus gain additional insights into immune infiltration patterns, tumor heterogeneity, and therapy resistance mechanisms.

Besides transcriptomic data integration, image-based deep learning methods are revolutionizing TIME characterization by extracting biologically relevant features from multiplexed histology and imaging data. Convolutional neural networks (CNNs) and generative adversarial networks (GANs) can decode high-dimensional spatial transcriptomics images, detecting immune cell distributions, tumor-immune interfaces, and microenvironmental alterations with high sensitivity [36]. AI-based histopathological analysis facilitates automatic annotation of immune cell infiltration patterns, creating predictive biomarkers of immunotherapy response. Furthermore, self-supervised and contrastive learning methods improve AI models' capacity to detect subtle spatial variations in immune-tumor interactions. By utilizing AI with spatial transcriptomics, researchers can create high-resolution immune landscapes, which lead to improved precision oncology and allow for the creation of targeted immunotherapies based on an individual's microenvironment [37].

Challenges and Limitations

While AI-empowered single-cell methods possess enormous transformative potential for the analysis of the tumor immune microenvironment (TIME), they are not without challenges and limitations that need to be addressed. Data quality and batch effects in single-cell measurements are major concerns. Single-cell transcriptomics and proteomics measurements are especially prone to technical noise, dropout events, and heterogeneity across experimental platforms, leading to batch effects that mask underlying

biological signals [38]. Standardization of data preprocessing protocols and design of computationally effective batch correction methods are essential to improve the reproducibility and reliability of single-cell research.

The most significant barrier arises because of interpretability issues and computational difficulties in AI models. Single-cell data are of a high dimension and require high computation power and sophisticated machine learning methods to interpret significant data. Still, deep models such as neural networks are "black boxes" in which the processes by which AI arrives at specific outcomes cannot be easily realized [39]. Enhancing the interpretability of such models through techniques like attention mechanisms, feature attribution, and interpretable AI frameworks is essential to building trust in AI-based biomedical research.

Another challenge is multi-omics data integration with AI. Integrating transcriptomics, proteomics, epigenomics, and spatial data can give a comprehensive view of TIME, but the heterogeneity of the data complicates integration [40]. Sophisticated AI methods like multimodal deep learning and graph models are being created to overcome this challenge, but optimization must be further improved to facilitate data fusion with ease and biological significance.

Finally, ethical, and clinical translation challenges need to be addressed. Use of artificial intelligence-based single-cell technologies in the clinic requires strict validation, regulatory approval, and development of ethical standards to avoid bias in model development, protect patient confidentiality, and provide equitable access to AI-based diagnostic and therapeutic modalities. Bridging the gap between AI research and clinical practice will require inter-

disciplinary cooperation between computational scientists, oncologists, and regulatory bodies to ensure that AI-based single-cell technologies can be safely and effectively deployed in precision oncology.

Future Perspectives and Emerging Trends

The future of AI-assisted single-cell analysis of the tumor immune microenvironment (TIME) is characterized by tremendous progress in the fields of multi-omics integration, personalized medicine, and the responsible use of AI technologies [41]. The intersection of AI-assisted single-cell multi-omics is becoming a potent method for unravelling the intricate interactions in TIME by combining various omics disciplines such as transcriptomics, proteomics, epigenomics, and metabolomics [42]. Sophisticated machine learning frameworks such as multimodal deep learning and graph neural networks are being developed to fuse these heterogeneous data, thereby facilitating a deeper understanding of immune-tumor interactions and the discovery of novel therapeutic targets.

Personalized medicine initiatives are another strong contender, with AI-driven single-cell analysis powering individualized anticancer treatment regimens. By analyzing the patient's own immune landscape, AI forecasts immunotherapy success, identifies synergistic combination therapy, and monitors real-time treatment resistance. Precision oncology based on AI is meant to enhance existing immune checkpoint blockade and other cancer immunotherapies by being able to match the intervention with the patient's own immune signature [43].




Fig 3: AI in Single-Cell Analysis and Precision Oncology

One of the cores focuses in artificial intelligence research is the development of explainable [44] AI (XAI) in the field of single-cell immunology, and it aims to offer solutions to model interpretability [45]. Currently existing deep learning models, although highly accurate, are "black boxes," and this makes it difficult to understand their decision-making processes. Other XAI approaches, such as attention mechanisms, feature attribution, and interpretable neural networks, aim to maximize transparency so that AI-based conclusions are biologically interpretable and clinically relevant.

Finally, federated learning will play a vital role in the sharing of data across multiple institutions, enabling cooperative AI training and maintaining patient confidentiality. By helping institutions train AI models on decentralized data with the security of the data maintained, federated learning can avoid issues of data availability,

diversity, and bias. This will streamline the development of robust AI models in cancer immunology, allowing collaborative global effort while offering diversified AI-based healthcare solutions. Since AI technologies evolve continuously, their integration with single-cell analysis will bring giant steps in cancer studies, ultimately revolutionizing immunotherapy and precision oncology [46].

Conclusion

The merging of single-cell technologies with the help of artificial intelligence has revolutionized the detection of the tumor immune microenvironment (TIME) in a groundbreaking manner, providing unprecedented insights into immune cell heterogeneity, tumor-immune cell interactions, and treatment responses. The combination of advanced single-cell techniques, such as single-cell RNA sequencing (scRNA-seq), mass cytometry, and spatial

transcriptomics, with AI-enabled analytical techniques allows scientists to decode complex immune landscapes with phenomenal accuracy. Machine learning algorithms aid feature selection, clustering, and predictive modelling, whereas deep learning algorithms enhance cell classification and mapping of immune interactions. Additionally, AI-enabled spatial transcriptomics helps with the better comprehension of immune infiltration patterns, thus facilitating the design of therapeutically driven spatial approaches.

The potential of these technologies in cancer immunology is vast. Single-cell analysis with the assistance of AI is speeding up biomarker discovery, improving predictability of response to immunotherapy, and turning personalized cancer therapy into a reality. By harnessing multi-omics data and interpretable AI, these technologies can facilitate enhanced clinical decision-making, translating to improved and targeted therapeutic interventions. Federated learning is also facilitating multi-institutional consortia, with the promise of diverse and representative data for AI training, mitigating biases and enhancing generalizability.

In the future, research will need to overcome computational limitations, improve AI interpretability, and uphold regulatory and ethical requirements in clinical translation. Ongoing development of AI-based approaches, combined with single-cell technologies, has the potential to revolutionize cancer immunology and precision oncology. In line with the increasing use of AI in biomedical research, its integration with single-cell technologies will inevitably pave the way for the next generation of cancer diagnostics and immunotherapeutic breakthroughs.

Table 4: List of Abbreviations

Abbreviation	Full Form
AI	Artificial Intelligence
ANN	Artificial Neural Networks
CNN	Convolutional Neural Networks
CyTOF	Cytometry by Time-of-Flight
DC	Dendritic Cells
GAN	Generative Adversarial Networks
ICI	Immune Checkpoint Inhibitor
MDSC	Myeloid-Derived Suppressor Cells
ML	Machine Learning
NK Cells	Natural Killer Cells
PCA	Principal Component Analysis
scRNA-seq	Single-cell RNA Sequencing
TILs	Tumor-Infiltrating Lymphocytes
TIME	Tumor Immune Microenvironment
TME	Tumor Microenvironment
t-SNE	t-distributed Stochastic Neighbour Embedding
UMAP	Uniform Manifold Approximation and Projection
XAI	Explainable Artificial Intelligence

References

- Desai SA, Patel VP, Bhosle KP, Nagare SD, Thombare KC. The tumor microenvironment: shaping cancer progression and treatment response. *J Chemother*. 2025 Jan 2;37(1):15-44.
- Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. *Nat Rev Immunol*. 2023 Feb;23(2):90-105.
- Yang YL, Yang F, Huang ZQ, *et al*. T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems. *Front Immunol*. 2023 Jun 30;14:1199173.
- Rastogi I, Jeon D, Moseman JE, *et al*. Role of B cells as antigen presenting cells. *Front Immunol*. 2022 Sep 8;13:954936.
- Pernot S, Evrard S, Khatib AM. The give-and-take interaction between the tumor microenvironment and immune cells regulating tumor progression and repression. *Front Immunol*. 2022 Apr 13;13:850856.
- Zhang H, Dai Z, Wu W, *et al*. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. *J Exp Clin Cancer Res*. 2021 Jun 4;40(1):184.
- Su X, Li J, Xu X, *et al*. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy. *J Transl Med*. 2024 Aug 9;22(1):751.
- Xu J, Qin S, Yi Y, *et al*. Delving into the heterogeneity of different breast cancer subtypes and the prognostic models utilizing scRNA-Seq and bulk RNA-Seq. *Int J Mol Sci*. 2022 Sep 1;23(17):9936.
- Slovin S, Carissimo A, Panariello F, *et al*. Single-cell RNA sequencing analysis: a step-by-step overview. In: *RNA Bioinformatics*. 2021:343-65.
- Wang X, He Y, Zhang Q, *et al*. Direct comparative analyses of 10X genomics chromium and smart-seq2. *Genomics Proteomics Bioinformatics*. 2021 Apr;19(2):253-66.
- Wu Y, Zhang K. Tools for the analysis of high-dimensional single-cell RNA sequencing data. *Nat Rev Nephrol*. 2020 Jul;16(7):408-21.
- Ren X, Zhang L, Zhang Y, *et al*. Insights gained from single-cell analysis of immune cells in the tumor microenvironment. *Annu Rev Immunol*. 2021 Apr 26;39(1):583-609.
- González-Silva L, Quevedo L, Varela I. Tumor functional heterogeneity unraveled by scRNA-seq technologies. *Trends Cancer*. 2020 Jan;6(1):13-9.
- Xu Y, Su GH, Ma D, *et al*. Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. *Signal Transduct Target Ther*. 2021 Aug 20;6(1):312.
- Hartmann FJ, Bendall SC. Immune monitoring using mass cytometry and related high-dimensional imaging approaches. *Nat Rev Rheumatol*. 2020 Feb;16(2):87-99.
- Johansson D, Rauld C, Roux J, *et al*. Mass cytometry of CSF identifies an MS-associated B-cell population. *Neuro Neuroimmunol Neuroinflamm*. 2021 Feb 15;8(2):e943.
- Yao L, Jayasinghe RG, Lee BH, *et al*. Comprehensive characterization of the multiple myeloma immune microenvironment using integrated scRNA-seq, CyTOF, and CITE-seq analysis. *Cancer Res Commun*. 2022 Oct 25;2(10):1255-65.
- Esaulova E. Understanding immune responses with single-cell RNA sequencing and CyTOF across different diseases and model organisms [dissertation]. St. Louis: Washington University; 2021.
- Labib M, Kelley SO. Single-cell analysis targeting the proteome. *Nat Rev Chem*. 2020 Mar;4(3):143-58.
- Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. *Front Pharmacol*. 2022 May 24;13:868695.

21. Phillips D, Schürch CM, Khodadoust MS, *et al.* Highly multiplexed phenotyping of immunoregulatory proteins in the tumor microenvironment by CODEX tissue imaging. *Front Immunol.* 2021 May 19;12:687673.
22. Lee J, Yoo M, Choi J. Recent advances in spatially resolved transcriptomics: challenges and opportunities. *BMB Rep.* 2022 Mar 31;55(3):113.
23. Vandereyken K, Sifrim A, Thienpont B, Voet T. Methods and applications for single-cell and spatial multi-omics. *Nat Rev Genet.* 2023 Aug;24(8):494-515.
24. Mittal M, Gujjar P, Prasad G, *et al.* Dimensionality reduction using UMAP and t-SNE technique. In: 2024 Second International Conference on Advances in Information Technology (ICAIT). 2024 Jul 24;1:1-5.
25. Javadi M, Aghighi H, Azadbakht M. Efficient graph partitioning using LouvainSplit algorithm.
26. Gui Y, He X, Yu J, Jing J. Artificial intelligence-assisted transcriptomic analysis to advance cancer immunotherapy. *J Clin Med.* 2023 Feb 6;12(4):1279.
27. Xu Y, Su GH, Ma D, *et al.* Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence. *Signal Transduct Target Ther.* 2021 Aug 20;6(1):312.
28. Ma H, Shi L, Zheng J, *et al.* Advanced machine learning unveils CD8+ T cell genetic markers enhancing prognosis and immunotherapy efficacy in breast cancer. *BMC Cancer.* 2024 Oct 1;24(1):1222.
29. Han W, Cheng Y, Chen J, *et al.* Self-supervised contrastive learning for integrative single cell RNA-seq data analysis. *Brief Bioinform.* 2022 Sep;23(5):bbac377.
30. Wu Z, Lawrence PJ, Ma A, *et al.* Single-cell techniques and deep learning in predicting drug response. *Trends Pharmacol Sci.* 2020 Dec;41(12):1050-65.
31. Yang Y, Zhao Y, Liu X, Huang J. Artificial intelligence for prediction of response to cancer immunotherapy. In: *Semin Cancer Biol.* 2022 Dec 1;87:137-47.
32. Hourani T, Holden JA, Li W, *et al.* Tumor associated macrophages: origin, recruitment, phenotypic diversity, and targeting. *Front Oncol.* 2021 Dec 20;11:788365.
33. Qin Y, Huo M, Liu X, Li SC. Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy. *Front Immunol.* 2024 Mar 8;15:1368749.
34. Zhang Z, Chen H, Yan D, *et al.* Deep learning identifies a T-cell exhaustion-dependent transcriptional signature for predicting clinical outcomes and response to immune checkpoint blockade. *Oncogenesis.* 2023 Jul 11;12(1):37.
35. Rao A, Barkley D, França GS, Yanai I. Exploring tissue architecture using spatial transcriptomics. *Nature.* 2021 Aug 12;596(7871):211-20.
36. Walsh LA, Quail DF. Decoding the tumor microenvironment with spatial technologies. *Nat Immunol.* 2023 Dec;24(12):1982-93.
37. Lee RY, Ng CW, Rajapakse MP, *et al.* The promise and challenge of spatial omics in dissecting tumour microenvironment and the role of AI. *Front Oncol.* 2023 May 1;13:1172314.
38. Eling N, Morgan MD, Marioni JC. Challenges in measuring and understanding biological noise. *Nat Rev Genet.* 2019 Sep;20(9):536-48.
39. Hassija V, Chamola V, Mahapatra A, *et al.* Interpreting black-box models: a review on explainable artificial intelligence. *Cogn Comput.* 2024 Jan;16(1):45-74.
40. Santiago-Rodriguez TM, Hollister EB. Multi 'omic data integration: A review of concepts, considerations, and approaches. *Semin Perinatol.* 2021 Oct 1;45(6):151456.
41. Jin J, Kim J. Multi-omics and artificial intelligence technology for elucidating disease pathophysiology.
42. Murmu S, Sinha D, Chaurasia H, *et al.* A review of artificial intelligence-assisted omics techniques in plant defense: current trends and future directions. *Front Plant Sci.* 2024 Mar 5;15:1292054.
43. Huss R, Raffler J, Märkl B. Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology. *Cancer Rep.* 2023 Jul;6(7):e1796.
44. Bunonyo KW, Ebiwareme L. Tumor growth mathematical modeling and application of chemo-immunotherapy and radiotherapy treatments. *Int J Stat Appl Math.* 2022;7(2):123-132. doi:10.22271/math.2022.v7.i2b.806.
45. Klauschen F, Dippel J, Keyl P, *et al.* Toward explainable artificial intelligence for precision pathology. *Annu Rev Pathol.* 2024 Jan 24;19(1):541-70.